Formulated for chronic hepatitis b to manage viral replication and support liver function stabilization.
Mechanism of Action
Lamivudine is phosphorylated to its active metabolite which competitively inhibits HBV polymerase. This results in the termination of the viral DNA chain and suppression of viral replication.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
12–24 hours
Contraindications
Hypersensitivity to lamivudine, Severe renal impairment
Severe Adverse Events
Lactic acidosis, Severe hepatomegaly, Post-treatment hepatitis b exacerbation — requires immediate medical attention
Information related to Epivir Hbv is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
